%0 Journal Article
%A Gambichler, Thilo
%A Iordanou, Maria
%A Becker, Jürgen C
%A Susok, Laura
%T Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
%J Melanoma research
%V 34
%N 1
%@ 0960-8931
%C [Erscheinungsort nicht ermittelbar]
%I Ovid
%M DKFZ-2023-02270
%P 80-83
%D 2024
%Z 2024 Feb 1;34(1):80-83 / Short communication
%X Intratumoural as well as systemic inflammation in melanoma has thoroughly been studied in the context of patients treated with immune checkpoint inhibitors but not with BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether parameters of intratumoral and systemic inflammation correlate with clinical outcome in patients with BRAF-mutant metastatic melanoma treated with BRAFi/MEKi. We studied 51 CM patients with unresectable stage III or IV who had the indication for BRAFi/MEKi treatment based on confirmed BRAF mutation. Baseline systemic immune-inflammation markers such as the systemic immune-inflammation index (SII) and the expression of intratumoral inflammation markers such as COX-2 protein expression were correlated with clinical outcome measures. On multivariable analyses, lower intratumoral COX-2 expression (OR 33.9, 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37924529
%R 10.1097/CMR.0000000000000934
%U https://inrepo02.dkfz.de/record/285235